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Abstract 
 
Background: Proinflammatory cytokines play an important role in the pathogenesis of heart 
failure. However, the mechanisms responsible for maintaining sterile inflammation within failing 
hearts remain poorly defined. Although transcriptional control is important for proinflammatory 
cytokine gene expression, the stability of the mRNA also contributes to the kinetics of immune 
responses. Regnase-1 is an RNase involved in the degradation of a set of proinflammatory 
cytokine mRNAs in immune cells. The role of Regnase-1 in non-immune cells such as 
cardiomyocytes remains to be elucidated. 
Methods: To examine the role of proinflammatory cytokine degradation by Regnase-1 in 
cardiomyocytes, cardiomyocyte-specific Regnase-1-deficient mice were generated. The mice 
were subjected to pressure overload by means of transverse aortic constriction (TAC) to induce 
heart failure. Cardiac remodeling was assessed by echocardiography as well as histological and 
molecular analyses 4 weeks after operation. Inflammatory cell infiltration was examined by 
immunostaining. Furthermore, interleukin-6 (IL-6) signaling was inhibited by the administration 
with its receptor antibody. Finally, overexpression of Regnase-1 in the heart was performed by 
adeno-associated viral vector-mediated gene transfer. 
Results: Cardiomyocyte-specific Regnase-1-deficient mice showed no cardiac phenotypes under 
baseline conditions, but exhibited severe inflammation and dilated cardiomyopathy after 4 weeks 
of pressure overload compared to the control littermates. Four weeks after TAC, the Il6 mRNA 
level was upregulated, but not other cytokine mRNAs including tumor necrosis factor- in 
Regnase-1-deficient hearts. Although the Il6 mRNA level increased 1 week after operation in 
both Regnase-1-deficient and control hearts, it showed no increase in control hearts 4 weeks after 
operation. Administration of anti-IL-6 receptor antibody attenuated the development of 
inflammation and cardiomyopathy in cardiomyocyte-specific Regnase-1-deficient mice. In 
severe pressure overloaded wild-type mouse hearts, sustained induction of Il6 mRNA was 
observed, even though the protein level of Regnase-1 increased. Adeno-associated virus 9-
mediated cardiomyocyte-targeted gene delivery of Regnase-1 or administration of anti-IL-6 
receptor antibody attenuated the development of cardiomyopathy induced by severe pressure 
overload in wild-type mice. 
Conclusions: The degradation of cytokine mRNA by Regnase-1 in cardiomyocytes plays an 
important role in restraining sterile inflammation in failing hearts and the Regnase-1-mediated 
pathway might be a therapeutic target to treat patients with heart failure. 
 
Key Words: heart failure; inflammation; Regnase-1; cytokine mRNA; interleukin-6 
 
Nonstandard Abbreviations and Acronyms 
TAC transverse aortic constriction 
IL-6 interleukin-6 
TNF-a tumor necrosis factor-a 
MCP-1 monocyte chemotactic protein-1 
MCPIP1 monocyte chemotactic protein-1-induced protein-1 
Mlc2v myosin light chain 2v 
sTAC severe transverse aortic constriction 
ITR inverted terminal repeats 
AAV adeno-associated virus 
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eGFP                     enhanced green fluorescent protein 
Reg-1 Regnase-1 
Reg1-AAV9 AAV type9 encoding FLAG-tagged Regnase-1 
eGFP-AAV9 AAV type9 encoding enhanced green fluorescent protein 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
TUNEL TdT-mediated dUTP-biotin nick end labeling 
qRT-PCR real-time quantitative reverse transcription PCR 
IL-1b interleukin 1 beta 
Nppa atrial natriuretic peptides 
Nppb brain natriuretic peptides 
Col1a2 collagen type I 2 chain 
Col3a1  collagen type III 1 chain 
IL12b interleukin 12b 
ANOVA one-way analysis of variance 
LVIDd end-diastolic left ventricular internal dimension 
LVIDs end-systolic left ventricular internal dimension 
FS fractional shortening 
HW/TL heart weight/tibia length 
LungW/TL lung weight/tibia length 
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Clinical Perspective 
 
What is new? 
• The degradation of cytokine mRNA by Regnase-1, a RNase, in cardiomyocytes plays an 
essential role in restraining inflammation in mouse pressure overload-induced failing 
hearts. 
• The major target for Regnase-1-mediated mRNA degradation appears to be IL-6 in 
cardiomyocytes. 
• Sustained increase in Il6 mRNA by deficiency or insufficient upregulation of Regnase-1 
in pressure-overloaded hearts promotes cardiac remodeling and inflammation. 
 
What are the clinical implications? 
• Failure of appropriate induction of Regnase-1 may underlie the persistent and chronic 
inflammation seen in chronic heart failure. 
• Upregulation of Regnase-1 function or IL-6 blockade may be a fruitful approach to 
therapeutic immunomodulation in heart failure patients with an increased level of IL-6. 
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Introduction 
Heart failure is the major cause of death in the developed countries. Circulating levels of 
proinflammatory cytokines including tumor necrosis factor- (TNF-) are increased in patients 
with heart failure and related to the severity and prognosis of the disease, although infection of 
microorganisms is not involved in most cases.1 This suggests an important role of sterile 
inflammation in the pathogenesis of chronic heart failure. However, the targeted anti-TNF 
approaches were negative with respect to the primary end points of the trial or resulted in 
worsening heart failure or death.2 In addition to TNF-, the pro-inflammatory cytokines that are 
elaborated in heart failure include other members of the tumor necrosis factor superfamily, 
members of the interleukin-1 family, and interleukin-6 (IL-6).1 Thus, the whole scheme how 
inflammation occurs in stressed hearts has to be elucidated to develop novel and effective 
therapeutics against heart failure. 
 We have previously reported that incomplete degradation of mitochondrial DNA by 
lysosomal DNase II in cardiomyocytes results in the initiation of inflammation and development 
of heart failure in pressure overload-induced mouse heart failure model.3 However, the 
mechanisms responsible for maintaining inflammatory responses within failing hearts remain 
poorly defined. Although transcriptional control is a determinant of the kinetics of 
proinflammatory cytokine gene expression, the stability of the mRNA also has a key function in 
coordinating immune responses.4 
 Regnase-1 (also known as Zc3h12a and monocyte chemotactic protein-1 (MCP-1)-
induced protein-1 (MCPIP1)) is an RNase that destabilizes a set of mRNAs, including IL-6 and 
IL-12b, through cleavage of their 3’ untranslated regions in macrophages.5 Regnase-1-deficient 
mice showed augmented serum immunoglobulin levels, autoantibody production and infiltration 
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of plasma cells to the lung. Macrophages isolated from Regnase-1-deficient mice showed 
increased production of IL-6 and IL-12p40 but not TNF. Although Regnase-1 is ubiquitously 
expressed, the role of Regnase-1 in non-immune cells such as cardiomyocytes has not been fully 
elucidated. 
 In this study, we generated cardiomyocyte-specific Regnase-1-deficient mice to elucidate 
the role of cytokine mRNA degradation in cardiomyocytes during cardiac remodeling. The 
results of this study indicate that cytokine mRNA degradation by Regnase-1 in cardiomyocytes 
is important in the maintenance of sterile inflammation and development of heart failure. 
 
Methods 
The data, analytic methods, and study materials are available from the corresponding author to 
other researchers on reasonable request for purposes of reproducing the results or replicating the 
procedure. 
Study Approval 
All in vivo and in vitro experimental protocols were approved by King’s College London Ethical 
Review Process Committee and UK Home Office (Project Licence No. PPL70/7260) and were 
performed in accordance with the Guidance on the Operation of the Animals (Scientific 
Procedures) Act, 1986 (UK Home Office). 
Generation of Cardiomyocyte-specific Regnase-1-deficient Mice. 
Mice bearing a Regnase-1flox allele6 were crossed with knock-in mice expressing Cre 
recombinase under the control of myosin light chain 2v (Mlc2v) promoter7 to produce 
cardiomyocyte-specific Regnase-1-deficient (Regnase-1flox/ flox;Mlc2v-Cre+) mice. All mice used 
were on the C57BL/6 and SV129 mixed background and 8- to 12-week-old male Regnase-1-
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deficient mice. Their littermates were used as controls. Mice were given food and water ad 
libitum. 
Isolation of Mouse Adult Cardiomyocytes 
Adult cardiomyocytes were isolated from 10- to 12-week-old male mice using a Langendorff 
system and cultured as we previously reported.3 
Echocardiography and Transverse Aortic Constriction 
A Vevo 2100 system with a 22–55 MHz linear transducer (Visual Sonics) was used to perform 
echocardiography on conscious mice.8 Non-invasive measurement of tail blood pressure was also 
performed on conscious mice using a BP Monitor for Rats and Mice (Muromachi Kikai) as 
previously described.8 The mice were subjected to thoracic transverse aortic constriction (TAC) 
and severe TAC (sTAC) using 26- and 27-gauge needles for aortic constriction, respectively.3 In 
TAC, a small piece of a 6-0 silk suture was placed between the innominate and left carotid 
arteries. Two loose knots were tied around the transverse aorta and a 26-gauge needle was placed 
parallel to the transverse aorta. The knots were quickly tied against the needle and the needle was 
promptly removed to yield a 26-gauge stenosis. In sTAC, aortic constriction was performed by 
tying a 6-0 silk suture against 27-gauge needle to yield a more severe constriction. Sham 
surgeries were identical except for the aortic constriction. 
Administration of MR16-1 
After TAC operation, Reg1+/+ and Reg1–/– mice received an intraperitoneal injection of 2 mg 
anti-mouse IL-6 receptor antibody MR16-1 (a kind gift from Chugai Pharmaceutical Co., Ltd.) 
or 2 mg control IgG (855951; MP Biomedicals). Afterwards they were injected intraperitoneally 
once a week with a total of three injections with either 0.5 mg MR16-1 or IgG.9 For the 
experiment to examine the effect of MR16-1 on cardiac remodeling in wild-type mice, sTAC-
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operated C57BL/6 mice received weekly injection with 0.15 mg MR16-1 or IgG from 1 week 
after sTAC. 
Virus Production and Infection 
FLAG-tagged Reg1 was cloned into inverted terminal repeats (ITR)-containing adeno-associated 
virus (AAV) plasmid harboring the chicken cardiac troponin T promoter (PL-C-PV1967, Penn 
Vector Core, University of Pennsylvania) after removal of enhanced green fluorescent protein 
(eGFP) sequence. AAV type 9 encoding FLAG-tagged Reganse-1 (Reg1-AAV9) was generated 
by transient transfection of HEK293 cells using three plasmids (the cis ITR-containing plasmid, 
the transplasmid encoding AAV replicase and capsid genes and the adenoviral helper plasmid) in 
Penn Vector Core. As a control, AV-9-PV1967 (Penn Vector Core) (eGFP-AAV9) was used. 
Eight- to 10-week-old C57BL/6 mice subjected to TAC operation were intraperitoneally injected 
with 1 x 1011 vector genomes of Reg1-AAV9 or eGFP-AAV9 1 week before surgery. 
Western Blot Analysis 
Total protein homogenates were subjected to western blot analysis using a monoclonal mouse 
antibody to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (G8795; SIGMA), a 
monoclonal rabbit antibody to Regnase-1 (generated by Prof. Akira),10 a monoclonal rabbit 
antibody to phospho-STAT3 (Tyr705) (#9145S; Cell Signaling) and a monoclonal mouse 
antibody to STAT3 (124H6) (#9139S; Cell Signaling).  After incubation with secondary 
antibody, the blot was developed with an infrared imaging system, ODYSSEY CLx (LI-COR 
Biosciences). Image Studio software (LI-COR Biosciences) was used for quantitative analysis to 
evaluate protein expression levels. 
Histological Analysis 
Left ventricle samples were embedded in the OCT compound (Thermo Fisher Scientific Inc.), 
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then immediately frozen in liquid nitrogen.8 The samples were sectioned into 6 m thickness and 
fixed with acetone. Hematoxylin-eosin staining and Masson’s trichrome staining (Masson’s 
Trichrome Stain Kit, Polysciences, Inc.) were performed on serial sections. For wheat germ 
agglutinin staining, heart samples were stained with FITC-conjugated lectin (SIGMA) to 
measure the cross-sectional area of cardiomyocytes. Quantitative analyses of fibrosis fraction 
and cardiomyocyte cross-sectional areas were examined in five different areas (magnification, 
x200) per section and measured using the NIH ImageJ software (National Institutes of Health). 
TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay was performed using an In situ 
Apoptosis Detection Kit (Takara Bio Inc.). The number of TUNEL-positive nuclei and total 
nuclei was counted. For immunohistochemical staining, avidin-peroxidase (VECTASTAIN Elite 
ABC Kit, Vector Laboratories, Inc.) and DAB Peroxidase Substrate Kit (Vector Laboratories, 
Inc.) were used, followed by counterstaining with hematoxylin as described previously.8 
Quantitative analyses of inflammatory cells were examined by counting the number of immuno-
positive cells in five different areas (magnification, x200) per section, and expressed as the 
number per millimeters squared.8 For these quantification in histology, two serial heart sections 
were prepared, then 3 different areas from mid-portion of free wall and 2 areas from mid-portion 
of septal wall in each sections were assessed. Images were analysed in a blinded fashion by two 
reviewers. The primary antibodies used were rat anti-CD45 (MAB114; R&D Systems, Inc.), rat 
anti-CD68 (MCA1957GA; AbD Serotec) or rabbit anti-CD68 antibody for immunofluorescence 
(ab125212; Abcam), rat anti-Ly6G/6C (550291; BD Biosciences), rabbit anti-CD3 (ab16669; 
Abcam), hamster anti-mouse CD11c antibody (MCA1369; Bio-Rad Laboratories, Inc.), and rat 
anti-mouse CD206 antibody (MCA2235; Bio-Rad Laboratories, Inc.). The secondary antibodies 
were goat anti-rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 568 
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(A-11036; Thermo Fisher Scientific Inc.), goat anti-hamster IgG (H+L) Secondary Antibody, 
Alexa Fluor 488 (A21110; Thermo Fisher Scientific Inc.), and goat anti-rat IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa Fluor 488 (A11006; Thermo Fisher Scientific Inc.). DAPI 
(ProLong Gold Antifade Reagent with DAPI; Life Technologies) was used to detect nuclei. 
Real-time Quantitative Reverse Transcription PCR (qRT-PCR) 
Total RNA was isolated from the left ventricles or isolated cardiomyocytes using TRIzol reagent 
(Thermo Fisher Scientific Inc.). The mRNA expression levels were determined by qRT-PCR 
using SuperScript II Reverse Transcriptase (Thermo Fisher Scientific Inc.) for reverse 
transcription and a Power SYBR Green PCR Master Mix (Thermo Fisher Scientific Inc.) for 
qRT-PCR reaction with PCR primers designed as follows: forward 5’ -
GAGTGGAAACGCTTCATCGAG-3’ and reverse 5’-AGGAAGTTGTCCAGGCTAGG-3’ for 
Regnase-1 (Reg1), forward 5’-ACAACCACGGCCTTCCCTACTT-3’ and reverse 5’-
CACGATTTCCCAGAGAACATGTG-3’ for interleukin 6 (Il6), forward 5’-
TCCCAGGTTCTCTTCAAGGGA-3’ and reverse 5’-GGTGAGGAGCACGTAGTCGG-3’ for 
tumor necrosis factor alpha (Tnfa), forward 5’- AAGAGCTTCAGGCAGGCAGTATCA-3’ 
and reverse 5’-TAATGGGAACGTCACACACCAGCA-3’ for interleukin 1 beta (Il1b), forward 
5’-TCGTCTTGGCCTTTTGGCT-3’ and reverse 5’-TCCAGGTGGTCTAGCAGGTTCT-3’ for 
atrial natriuretic peptides (Nppa), forward 5’-AAGTCCTAGCCAGTCTCCAGA-3’ and reverse 
5’-GAGCTGTCTCTGGGCCATTTC-3’ for brain natriuretic peptides (Nppb), forward 5’-
ACGCGGACTCTGTTGCTGCT-3’ and reverse 5’-GCGGGACCCCTTTGTCCACG-3’ for 
collagen type I alpha 2 (Co1a2), forward 5’-CCCGGGTGCTCCTGGACAGA-3’ and reverse 5’-
CACCCTGAGGACCAGGCGGA-3’ for collagen type III alpha 1 (Col3a1), and forward 5’-
ATGACAACTTTGTCAAGCTCATTT-3’ and reverse 5’-GGTCCACCACCCTGTTGCT-3’ for 
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Gapdh. 8 The PCR primers for interleukin 12b (Il12b) (Mm01288989_m1), interferon b1 (Ifnb1) 
(Mm 00439552_s1), interferon gamma (Ifng) (Mm01168134_m1), and interleukin 10 (Il10) 
(Mm01288386_m1) were purchased from Thermo Fisher Scientific Inc. The TaqMan Gene 
Expression Master Mix (Thermo Fisher Scientific Inc.) was used for amplification of Il12b, 
Ifnb1, Ifng, and Il10. PCR standard curves were constructed using the corresponding 
complementary DNA and all data were normalized to Gapdh mRNA content and are expressed 
as fold increase over the control group. 
In Situ Hybridization 
In situ hybridization was performed using the QuantiGene ViewRNA Chromogenic Signal 
Amplificatoion Kit (Affymetrix eBioscience), the QuantiGene ViewRNA ISH Tissue 1-Plex 
Assay Kit (Affymetrix eBioscience), and the ViewRNA Probe MOUSE Il6 (Affymetrix 
eBioscience) according to the manufacturer’s instructions. After frozen tissue slides were fixed 
in 10% neutral buffered formalin at 4°C for 16 h, the slides were dehydrated and digested with 
protease. Hybridization with the probe for Il6 mRNA was performed, followed by signal 
amplification and signal detection steps. After washing in phosphate-buffered saline, the slides 
were incubated with an anti--sarcomeric actin (A2172; SIGMA) and chicken anti-mouse IgG 
(H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (A-21200; Thermo Fisher 
Scientific Inc.). 
Statistics 
Results are shown as mean ± SEM. Paired data were evaluated by Student's t-test which was 
used for two groups comparison and one-way analysis of variance (ANOVA) with the 
Bonferroni's post hoc test for multiple comparisons. P < 0.05 was considered statistically 
significant.  
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Results 
Regnase-1-deficient Mice Had No Cardiac Phenotypes at Baseline 
To examine the in vivo role of Regnase-1 in cardiomyocytes, mice with a Regnase-1flox allele6 
were crossed with knock-in mice expressing Cre recombinase under the control of Mlc2v 
promoter7, to produce Regnase-1flox/flox;Mlc2v-Cre+ (Reg1–/–) mice. Regnase-1flox/flox;Mlc2v-Cre– 
(Reg1+/+) littermates were used as controls. The Reg1–/– mice were born at Mendelian frequency 
and grew to adulthood. In Reg1–/– hearts, there was a significant reduction in the protein level of 
Regnase-1 (Figure IA in the online-only Data Supplement). The deletion of Reg1 was confirmed 
in isolated cardiomyocytes by qRT-PCR (Figure IB in the online-only Data Supplement). There 
were no significant differences in physiological and echocardiographic parameters between 
Reg1+/+ and Reg1–/– mice (Table I in the online-only Data Supplement), indicating that the Reg1–
/– mice had normal global cardiac structure and function. 
Regnase-1-deficient Mice Developed Heart Failure in Response to Pressure Overload. 
To determine the role of Regnase-1 during cardiac remodeling, Reg1+/+ and Reg1–/– mice were 
subjected to pressure overload by means of TAC.11 There was no difference in the survival ratio 
between TAC-operated Reg1–/– mice (8.3%, 1 out of 12 mice) and TAC-operated Reg1+/+ (0%, 0 
out of 13 mice). The Reg1+/+ and Reg1–/– mice exhibited left chamber dilatation and cardiac 
dysfunction 4 weeks after TAC (Figure 1A and B). However, the extent was more severe in 
Reg1–/– mice. Although TAC induced an increase in the heart weight-to-tibia length ratio in both 
groups, the ratio was larger in Reg1–/– mice (Figure 1C). The lung weight-to-tibia length ratio 
was elevated in TAC-operated Reg1–/– mice, but not in Reg1+/+ mice (Figure 1C). TAC-operated 
Reg1–/– hearts exhibited intermuscular cell infiltration (Figure 1D). Interstitial fibrosis was 
present in TAC-operated Reg1–/– hearts (Figure 1E). The cardiomyocyte cross-sectional area in 
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TAC-operated Reg1–/– mice was larger than in TAC-operated Reg1+/+ mice (Figure 1F). The 
mRNA levels of Nppa and Nppb increased in both TAC-operated Reg1+/+ and Reg1–/– hearts, but 
were higher in TAC-operated Reg1–/– hearts (Figure 1G).  The mRNA expression of Col3a1 in 
TAC-operated Reg1–/– hearts was higher than in TAC-operated Reg1+/+ hearts (Figure 1G). The 
number of apoptotic cardiomyocytes increased in TAC-operated Reg1–/– hearts (Figure IIA and 
B in the online-only Data Supplement). These data suggest that ablation of Regnase-1 in 
cardiomyocytes resulted in severe cardiac chamber dilatation, dysfunction, hypertrophy and 
fibrosis and lung congestion in response to pressure overload. 
Cardiomyocyte-specific Deletion of Regnase-1 in Pressure-overloaded Hearts Resulted in 
the Development of Inflammation with a Specific Increase in Il6 mRNA. 
Four weeks after TAC, the Il6 mRNA level was upregulated, but not other cytokine mRNAs 
including Tnfa and Il12b (a known Regnase-1 target)5, in TAC-operated Reg1–/– hearts compared 
to the corresponding sham-operated and TAC-operated Reg1+/+ hearts  (Figure 2A). The Il6 
mRNA level was not significantly increased in TAC-operated Reg1+/+ hearts compared to sham-
operated Reg1+/+ hearts (Figure 2A). A higher number of CD45+, CD68+, and CD3+, but not 
Ly6G+ cells infiltrated TAC-operated Reg1–/– hearts than TAC-operated Reg1+/+ hearts (Figure 
2B–E). Most inflammatory cells were CD68+ macrophages, especially CD206+ M2-macrophages 
(Figure 3A–C). The in situ hybridization analysis indicates that a higher number of 
cardiomyocytes expressed Il6 mRNA in Reg1–/– hearts compared to Reg1+/+ hearts under 
pressure overload (Figure 3D). In contrast to the results 4 weeks after TAC, Il6 and Tnfa mRNAs 
increased in both TAC-operated Reg1+/+ and Reg1–/– hearts and there was no significant 
difference in the level of the cytokine mRNAs between the two groups 1 week after TAC (Figure 
3E). Phosphorylation of STAT3, a downstream of IL-6 signaling pathway, was increased in 
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TAC-operated Reg1–/– hearts compared to TAC-operated Reg1+/+ hearts (Figure IIC in the 
online-only Data Supplement). Thus, deficiency of Regnase-1 in cardiomyocytes caused 
sustained induction of Il6 mRNA with severe infiltration of inflammatory cells in the heart in 
response to pressure overload. 
IL-6 Blockade Attenuated Inflammation and Heart Failure in Regnase-1-deficient Mice  
To examine whether the persistent elevation of Il6 mRNA is a cause for pressure overload-
induced heart failure in Reg1–/– mice, IL-6 signaling was blocked using a monoclonal antibody 
against the IL-6 receptor (MR16-1) after TAC surgery.9 Control IgG or MR16-1 had no effect on 
cardiac chamber size and function and heart and lung weight in sham-operated Reg1+/+ and 
Reg1–/– mice (Figure IIE and F in the online-only Data Supplement). MR16-1 attenuated the 
chamber dilatation, cardiac dysfunction and hypertrophy induced by TAC in Reg1–/– mice 
(Figure 4A–C). Furthermore, MR16-1 attenuated non-cardiomyocyte cell infiltration, fibrosis, 
the increase in cardiomyocyte cross-sectional area, the upregulation of Nppa mRNA, and the 
increase in number of apoptotic cardiomyocytes (Figure 4D–G and Figure IID in the online-only 
Data Supplement). Infiltration of CD45+ and CD68+ cells was also inhibited by MR16-1 (Figure 
5A–D). In contrast, MR16-1 had no beneficial effect on cardiac abnormalities observed in 
Reg1+/+ mice, which exhibited no increase in Il6 mRNA 4 weeks after TAC (Figure 4A–C). 
Severe Pressure Overload Induced Sustained Il6 mRNA Upregulation in Hearts 
Since the plasma level of IL-6 in the patients with heart failure was related with its severity12, 
severe pressure overload, sTAC, may increase the level of Il6 mRNA in mouse failing hearts. 
The wild-type C57BL/6 mice showed chamber dilatation, cardiac dysfunction and lung 
congestion 1 and 4 weeks after sTAC (Figure IIIA and B in the online-only Data Supplement). 
Non-cardiomyocyte infiltration, fibrosis, infiltration of CD45+ and CD68+ cells and upregulation 
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of Nppa, Nppb, Col1a2 and Col3a1 mRNAs were observed 4 weeks after sTAC (Figure IIIC and 
D in the online-only Data Supplement). The levels of Il6 and Tnfa mRNA in the hearts increased 
1 week after sTAC compared to those in sham-operated hearts and the level of Il1b mRNA was 
not different between sTAC- and sham-operated hearts 1 week after surgery (Figure IIIE–G in 
the online-only Data Supplement). The level of Il6 mRNA was higher in sTAC-operated hearts 
than that in sham-operated hearts 4 weeks after sTAC, whereas the levels of Tnfa and Il1b 
mRNA showed no difference between sTAC- and sham-operated hearts 4 weeks after surgery 
(Figure IIIE–G in the online-only Data Supplement). Thus, we switched to a sTAC model to 
examine the effect of overexpression of Regnase-1 or administration of MR16-1 in wild-type 
mice, in which Il6 mRNA was upregulated. 
Reg1–/– mice exhibited more severe left chamber dilatation and cardiac dysfunction 4 
weeks after sTAC, compared to Reg1+/+ mice (Figure IIIH and I in the online-only Data 
Supplement) as observed in TAC-operated Reg1+/+ and Reg1–/– mice. 
Regnase-1 Overexpression or IL-6 Blockade in Wild-type Hearts Attenuated Heart Failure 
Upper and lower bands on Western blot represent phosphorylated and non-phosphorylated 
Regnase-110 in sTAC-operated wild-type C57BL/6 hearts 4 weeks after surgery (Figure IIIJ in 
the online–only Data Supplement), respectively, which of both exhibited reduced density in 
Reg1–/– hearts (Figure IA in the online-only Data Supplement). Protein levels of non-
phosphorylated Regnase-1 and total Regnase-1 significantly increased in sTAC-operated mouse 
hearts, but there was no significant difference in phosphorylated Regnase-1 between sham- and 
sTAC-operated hearts (Figure IIIJ in the online-only Data Supplement). To test whether 
insufficient induction of Regnase-1 during cardiac remodeling may lead to the sustained 
upregulation of Il6 mRNA, Reganse-1 was overexpressed in wild-type mouse cardiomyocytes by 
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infection of recombinant adeno-associated virus 9 encoding FLAG-tagged Reganse-1 (Reg1-
AAV9) under the control of cardiac troponin T promoter. One week after intraperitoneal 
injection with AAV9 expressing Regnase-1 or eGFP (eGFP-AAV9), wild-type mice were 
subjected to sTAC. There were no significant differences in cardiac function 1 week after the 
infection between the two groups (Table II in the online-only Data Supplement). The mice were 
observed for 4 weeks after surgery. Infection of Reg1-AAV9 resulted in 8.4-fold increase in 
Regnase-1 protein level in the hearts compared to control infected with eGFP-AAV9 (Figure 
IVA in the online-only Data Supplement). There was no significant difference in the mortality in 
Reg1-AAV9-infected mice (21.1%, 4 out of 19 mice) and that in control vector-infected mice 
(21.4%, 3 out of 14 mice). Echocardiography revealed improvement in cardiac chamber 
dilatation and function in Reg1-AAV9-infected mice compared to control vector-infected mice 
(Figure 6A and B). Regnase-1 overexpression reduced the ratio of lung weight-to-tibia length 
(Figure 6C) and attenuated non-cardiomyocyte cell infiltration, fibrosis, upregulation of Nppa 
and Nppb mRNAs (Figure 6D–F) and infiltration of CD45+ and CD68+ cells (Figure 7A and B), 
and decreased Il6 mRNA level (Figure 7C) in sTAC-operated hearts. Interestingly, 
overexpression of Regnase-1 did not show beneficial effects on left chamber dilatation and 
cardiac dysfunction induced by TAC in wild-type mice, in which the level of Il6 mRNA was not 
significantly increased (Figure IVB–D in the online-only Data Supplement). 
Next, we examined the effect of MR-1 on cardiac remodeling after sTAC in wild-type 
mice. Since IgG (0.5 mg) administration seems to have a non-specific cardioprotective effect 
(Figure 1 and 4), we examined the dose-dependent effect of IgG on cardiac remodeling. 
C57BL/6 mice were subjected to sTAC operation and received intraperitoneal injection of 
various doses of IgG (0, 0.15, or 0.50 mg) once a week from one week after operation. The 0.15 
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mg of IgG had no effect on left chamber dilation and cardiac dysfunction, while 0.5 mg of IgG 
attenuated the development of cardiac remodeling (Figure VA in the online-only Data 
Supplement). Thus, 0.15 mg IgG or MR-1 were injected to the mice to examine the effect of IL-6 
blockade on cardiac remodeling. MR16-1 attenuated LV dilatation, cardiac dysfunction, 
hypertrophy, lung congestion and fibrosis induced by sTAC in wild-type mice (Figure VB–D in 
the online-only Data Supplement). 
 
Discussion 
Our data indicate that during normal embryonic development, there is no cardiac myocyte-
autonomous requirement for the Regnase-1 signaling pathway. Furthermore, the Regnase-1-
mediated pathway does not appear to be required for normal heart growth in the postnatal period. 
In response to pressure overload, Regnase-1 plays a protective role against the development of 
heart failure. 
In Reg1–/– mice, Il6 mRNA levels increased 1 and 4 weeks after TAC, while in Reg1+/+ 
mice, the cytokine mRNA was upregulated 1 week after TAC, but not 4 weeks after TAC. Il6 
mRNA is known to be a target of Regnase-1.5 Thus, Il6 mRNA degradation by Regnase-1 in 
cardiomyocytes regulates the time course of its expression level in the heart. Protective effects of 
MR16-1 in Reg1–/– mice indicate that the observed cardiac phenotypes in Reg1–/– mice is, at least 
in a part, due to the continuous elevation of Il6 mRNA. However, the lack of beneficial effect of 
MR16-1 on cardiac contractility in Reg1+/+ mice indicates that cardiac dysfunction observed in 
Reg1+/+ mice is IL6-independent. Inhibition of IL-6 reduced fibrosis and apoptosis in TAC-
operated Reg1–/– mice and overexpression of Regnase-1 and inhibition of IL-6 reduced fibrosis in 
sTAC-operated wild-type mice, suggesting the loss of cardiomyocytes is involved in IL-6-
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mediated cardiac dysfunction. It has been reported that IL-6 decreases cardiac contractility via 
STAT3-nitric oxide-dependent pathway.13 We observed the increased activation of STAT3 in 
TAC-operated Reg1–/– mice, indicating the negative inotropic effect of IL-6 may also be 
involved in the pathogenesis. 
No significant increase in Il12b mRNA (a known Regnase-1 target) was observed in 
Reg1+/+ and Reg1–/– hearts 4 weeks after TAC. The major target for Regnase-1-mediated mRNA 
degradation appears to be IL-6 in cardiomyocytes. In T cells, Regnase-1 regulates the production 
of interferon-  mRNA, while in macrophages, it regulates the degradation of Il6 and Il12p40 
mRNAs.5 The target of Regnase-1 seems to be cell type-specific. 
Our data showed that the time course of Il6 mRNA level during cardiac remodeling 
depends on the strength of the stress. This is in agreement with the clinical study that the plasma 
level of IL-6 in the patients with heart failure was related with its severity.12 To know the role of 
myocardial Regnase-1 upregulation during cardiac remodeling, we employed the severe TAC 
model, in which Il6 mRNA showed continuous upregulation until 4 weeks after operation. 
Overexpression of Regnase-1 in cardiomyocytes decreased Il6 mRNA level in the heart and 
attenuated the development of myocardial inflammation and heart failure in sTAC-operated 
wild-type mouse model. Thus, upregulation of Regnase-1 is a protective mechanism to prevent 
hearts against pressure overload and the level of its upregulation is insufficient to suppress the 
development of inflammation and dilated cardiomyopathy. MR16-1 attenuated the development 
of cardiac remodeling in sTAC-operated wild-type mice. Practical point would be that targeting 
IL-6 might be a fruitful treatment for patients with a high level of IL-6. In addition, cytokine 
mRNA degradation in cardiomyocytes may be a new potential target for the therapy of heart 
failure. 
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Regnase-1 was reported to be MCPIP1.14 MCP-1 is the main chemotactic factor for 
migration of monocyte/macrophages and the pathogenesis of chronic inflammation.15 
Cardiomyocyte-targeted expression of MCP-1 in mice resulted in the induction of MCPIP1 and 
development of cardiac dysfunction with an increased number of apoptotic cardiomyocytes.14 
However, the present study shows that Reganase-1 protects the heart against hemodynamic 
stress, inconsistent with these reports showing the detrimental role of MCP-1-MCPIP1 pathways. 
Excessive overexpression of Regnase-1 from the embryonic stage might be detrimental to the 
heart. 
In conclusion, the data suggest that the degradation of cytokine mRNA, as well as 
mitochondrial DNA, in non-immune cardiomyocytes is critical for restraining inflammation in 
failing hearts. The Regnase-1-related signaling pathway in cardiomyocytes is a potential 
therapeutic target to treat patients with heart failure. 
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Figure Legends 
 
Figure 1. Pressure overload-induced cardiomyopathy in Reg1–/– mice. The Reg1+/+ and Reg1–
/– mice were subjected to pressure overload by means of transverse aortic constriction (TAC). 
The mice were analyzed 4 weeks after TAC. Data were evaluated by one-way analysis of 
variance (ANOVA) with the Bonferroni's post hoc test. Data are mean ± SEM. *P<0.05, **P< 
0.01, ***P<0.001.  A, M-mode echocardiographic tracings from sham- or TAC-operated Reg1+/+ 
or Reg1–/– mice. Scale bars, 0.1 sec and 2 mm. B and C, Echocardiographic (B) and 
physiological (C) parameters. N=7 (sham-Reg1+/+), 7 (TAC-Reg1+/+), 7 (sham-Reg1–/–) or 6 
(TAC-Reg1–/–) per group. LVIDd and LVIDs, end-diastolic and end-systolic left ventricular 
internal dimension, respectively. FS, fractional shortening; HW/TL, heart weight/tibia length; 
LungW/TL, lung weight/TL. D–F, Hematoxylin-eosin-stained (D), Masson’s trichrome-stained 
(E), and wheat germ agglutinin-stained (F) heart sections. Scale bar, 100 m. Fibrosis fraction 
was measured (N=3). Cardiomyocyte cross-sectional area was measured by tracing the outline of 
70 myocytes in non-fibrotic area in each section (N=3). G, mRNA expression of Nppa, Nppb, 
Col1a2, and Col3a1. N=5 (sham-Reg1+/+), 4 (TAC-Reg1+/+), 5 (sham-Reg1–/–) or 5   
(TAC-Reg1–/–) per group. Gapdh mRNA was used as the loading control. The averaged value in 
sham-operated Reg1+/+ hearts was set equal to 1. 
 
Figure 2. Inflammatory responses in pressure-overloaded Reg1–/– hearts.  The Reg1+/+ and 
Reg1–/– mice subjected to TAC were analyzed 4 weeks after TAC. Data were evaluated by one-
way ANOVA with the Bonferroni's post hoc test. Data are mean ± SEM. *P<0.05, **P< 0.01, 
***P<0.001. A, Inflammatory cytokine mRNAs including Tnfa, Il6, Il1b, Il12b, Ifnb1, Ifng and 
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Il10. N=5 (sham-Reg1+/+), 4 (TAC-Reg1+/+), 5 (sham-Reg1–/–) or 5 (TAC-Reg1–/–) per group. 
Gapdh mRNA was used as the loading control. The averaged value in sham-operated Reg1+/+ 
mice was set equal to 1. B–E, Immunohistochemical analysis for CD45 (B), CD68 (C), CD3 (D), 
and Ly6G (E). Scale bar, 100 m. Bottom graphs show quantitative analysis of each infiltrating 
inflammatory cell-type (N=3). 
 
Figure 3. Production of Il6 mRNA in Reg1–/– hearts under pressure overload. Reg1+/+ and 
Reg1–/– hearts 4 weeks (A–D) or 1 week (E) after TAC were analyzed. Data were evaluated by 
Student’s t-test (C and D) or one-way ANOVA with the Bonferroni's post hoc test (E). Data are 
mean ± SEM. *P<0.05, ***P<0.001. A, Double staining of TAC-operated Reg1–/– heart sections 
with anti-CD68 (red) and anti-CD11c (green) antibodies. B, Double staining of TAC-operated 
Reg1–/– heart sections with anti-CD68 (red) and anti-CD206 (green) antibodies. Scale bar, 100 
m. C, The ratio of CD11c- or CD206-positive to CD68-postive cell number (N=3). D, In situ 
hybridization for Il6 mRNA (red) in Reg1+/+ or Reg1–/– hearts, followed by immunostaining with 
-sarcomeric action antibody (green). Scale bar, 100 m. Right graph shows the number of red 
dots in cardiomyocytes. E, Tnfa and Il6 mRNA levels 1 week after TAC. N=5 (sham-Reg1+/+), 5 
(TAC-Reg1+/+), 5 (sham-Reg1–/–) or 6 (TAC-Reg1–/–) per group. Gapdh mRNA was used as the 
loading control. The averaged value in sham-operated Reg1+/+ mice was set equal to 1. 
 
Figure 4. IL-6 blockade ameliorated TAC-induced cardiomyopathy in Reg1–/– mice. After 
TAC operation, Reg1+/+ and Reg1–/– mice received an intraperitoneal injection of anti-mouse IL-
6 receptor antibody MR16-1 or control IgG. Afterwards they were injected intraperitoneally once 
a week with a total of three injections with either MR16-1 or IgG.  The mice were analyzed 4 
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weeks after TAC. Data were evaluated by one-way ANOVA with the Bonferroni's post hoc test. 
Data are mean ± SEM. *P<0.05, **P< 0.01, ***P<0.001. A, M-mode echocardiographic tracings 
from IgG-treated or MR16-1-treated Reg1+/+ or Reg1–/– mice. Scale bars, 0.1 sec and 2 mm. B 
and C, Echocardiographic (B) and physiological (C) parameters. N=7 (IgG-Reg1+/+), 8 (IgG-
Reg1–/–), 6 (MR16-1-Reg1+/+) or 8 (MR16-1-Reg1–/–) per group. D–F, Hematoxylin-eosin-
stained (D), Masson’s trichrome-stained (E), and wheat germ agglutinin stained (F) heart 
sections. Scale bar, 100 m. Fibrosis fraction (N=5) and cross-sectional area of cardiomyocytes 
(N=3) were measured. G, mRNA expression of Nppa and Nppb. N=6 (IgG-Reg1+/+), 5 (IgG-
Reg1–/–), 5 (MR16-1-Reg1+/+) or 5 (MR16-1-Reg1–/–) per group. Gapdh mRNA was used as the 
loading control. The averaged value in TAC-operated Reg1+/+ hearts treated with IgG was set 
equal to 1. 
 
Figure 5. IL-6 blockade inhibited infiltration of inflammatory cells. TAC-operated Reg1+/+ 
and Reg1–/– hearts treated with anti-mouse IL-6 receptor antibody MR16-1 or control IgG were 
analyzed. Data were evaluated by one-way ANOVA with the Bonferroni's post hoc test. Data are 
mean ± SEM. *P<0.05, **P< 0.01. A–D, Immunohistochemical analysis for CD45 (A), CD68 
(B), CD3 (C), and Ly6G (D). Scale bar, 100 m. Bottom graphs show quantitative analysis of 
each infiltrating inflammatory cell-type (N=3). 
 
Figure 6. Overexpression of Regnase-1 protein attenuated severe TAC-induced heart 
failure. Wild-type C57BL/6 mice were intraperitoneally injected with AAV9 expressing eGFP 
(eGFP-AAV9) or Regnase-1 (Reg1-AAV9) and were subjected to severe TAC (sTAC) 1 week 
after infection. Sham- or sTAC-operated wild type mice infected with eGFP-AAV9 (eGFP-sham 
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or eGFP-sTAC) or Reg1-AAV9 (Reg1-sham or Reg1-sTAC) were analyzed 4 weeks after 
operation. Data were evaluated by one-way ANOVA with the Bonferroni's post hoc test. Data 
are mean ± SEM. *P<0.05, **P< 0.01, ***P<0.001. A, M-mode echocardiographic tracings from 
eGFP-sham, eGFP-sTAC, Reg1-sham or Reg1-sTAC wild-type mice. Scale bars, 0.1 sec and 2 
mm. B and C, Echocardiographic (B) and physiological (C) parameters. N=16 (eGFP-sham), 11 
(eGFP-sTAC), 16 (Reg1-sham) or 15 (Reg1-sTAC). D and E, Hematoxylin-eosin-stained (D) 
and Masson’s trichrome-stained (E) heart sections. Scale bar, 100 m. Fibrosis fraction was 
evaluated. N=3 (eGFP- or Reg1-sham) or 4 (eGFP- or Reg1-sTAC). F, mRNA expressions of 
Nppa and Nppb. N=7 (eGFP-sham), 6 (eGFP-sTAC), 7 (Reg1-sham) or 7 (Reg1-sTAC). Gapdh 
mRNA was used as the loading control. The averaged value in eGFP-sham group was set equal 
to 1. 
 
Figure 7. Induction of Regnase-1 protein suppressed the extent of inflammatory responses 
in severe TAC-induced heart failure. Severe TAC-operated wild-type C57BL/6 mice infected 
with AAV9 expressing eGFP (eGFP-sTAC) or Regnase-1 (Reg1-sTAC) were analyzed. Data 
were evaluated by one-way ANOVA with the Bonferroni's post hoc test. Data are mean ± SEM. 
*P<0.05, ***P<0.001. A and B, Immunohistochemical analysis for CD45 (A) and CD68 (B). 
Scale bar, 100 m. Bottom graphs show quantitative analysis of each infiltrating inflammatory 
cell-type in eGFP-sham, eGFP-sTAC, Reg-1-sham or Reg1-sTAC hearts (N=3). C, Il6 mRNA 
expressions. N=7 (eGFP-sham), 6 (eGFP-sTAC), 7 (Reg1-sham) or 7 (Reg1-sTAC). Gapdh 
mRNA was used as the loading control. The averaged value in eGFP-sham group was set equal 
to 1. 
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